National Institutes of Health (October 21, 2010): Foundation for NIH Announces Renewal of the Alzheimer's Disease Neuroimaging Initiative (ADNI)

Publication Date: 
Thu, 10/21/2010

The Foundation for the National Institutes of Health announced today that the National Institutes of Health’s Alzheimer’s Disease Neuroimaging Initiative (ADNI) - the largest public-private partnership in Alzheimer’s disease research – has been renewed for an additional five years.

The aim of the study expansion, called ADNI2, is to gain new insights into the onset and progression of Alzheimer’s disease, with the goal of improving clinical trial design and aiding drug development. ADNI2 will seek to identify and track early changes in the brain before the onset of symptoms of Alzheimer’s disease by using imaging techniques and biomarker measures in blood and cerebrospinal fluid.

"The study’s chief goal is to identify biomarkers that recognize Alzheimer's disease at an early stage and monitor progression and response to treatment,” noted Dr. Michael Weiner, ADNI Principal Investigator; Professor of Medicine, Radiology, Psychiatry, and Neurology, University of California, San Francisco; and Director, Center for Imaging of Neurodegenerative Disease, San Francisco Veteran’s Administration Medical Center.

“This grant renewal will fund enrollment and continued measurement of more than 1,000 subjects including healthy elders, people with mild cognitive impairment, and patients with dementia due to Alzheimer's disease. The continuation of ADNI will accelerate the development of diagnostic methods and clinical treatment trials, helping to develop effective therapies to prevent Alzheimer's disease," concluded Weiner.